Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130742 | 0.84 | LMNA (0.32) | LMNAMAPTCYP2C9 | |
| SCHEMBL4125695 | 0.72 | LMNA (0.44) | LMNAMAPTCYP2C9 | |
| SCHEMBL4123863 | 0.71 | KDM4E (0.32) | LMNAMAPT | |
| SCHEMBL4147195 | 0.70 | — | — | |
| SCHEMBL4125776 | 0.68 | LMNA (0.35) | LMNAMAPTCYP2C9 | |
| SCHEMBL4136463 | 0.68 | GAA (0.30) | MAPT | |
| SCHEMBL4134595 | 0.67 | — | — | |
| SCHEMBL4125701 | 0.67 | — | — | |
| SCHEMBL4140290 | 0.67 | — | — | |
| SCHEMBL4125708 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009032179-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090060867-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060867-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060867-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060867-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI | POLR2E, POLR2H, POLI | LMNA 4210/4885MAPT 3873/4885CYP2C9 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.